These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10165460)

  • 21. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Menopause Int; 2009 Mar; 15(1):19-25. PubMed ID: 19237618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
    Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes measurement: health state preferences and economic evaluation.
    Oldridge NB
    Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 28. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risks, benefits and costs of hormone replacement therapy in menopause].
    Gaspard U
    Rev Med Liege; 1998 May; 53(5):298-304. PubMed ID: 9689887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Setting priorities in and for end-of-life care: challenges in the application of economic evaluation.
    Normand C
    Health Econ Policy Law; 2012 Oct; 7(4):431-9. PubMed ID: 23079301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A computer model to analyze the cost-effectiveness of hormone replacement therapy.
    Zethraeus N; Johannesson M; Jönsson B
    Int J Technol Assess Health Care; 1999; 15(2):352-65. PubMed ID: 10507194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.
    Velentzis LS; Salagame U; Canfell K
    BMC Health Serv Res; 2017 May; 17(1):326. PubMed ID: 28476121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.
    Stevenson M; Pandor A; Martyn-St James M; Rafia R; Uttley L; Stevens J; Sanderson J; Wong R; Perkins GD; McMullan R; Dark P
    Health Technol Assess; 2016 Jun; 20(46):1-246. PubMed ID: 27355222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating country-specific cost-effectiveness from multinational clinical trials.
    Willke RJ; Glick HA; Polsky D; Schulman K
    Health Econ; 1998 Sep; 7(6):481-93. PubMed ID: 9809707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of hormone therapy in the United States.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    J Womens Health (Larchmt); 2009 Oct; 18(10):1669-77. PubMed ID: 19857096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation: an introduction.
    Raftery J
    BMJ; 1998 Mar; 316(7136):1013-4. PubMed ID: 9550969
    [No Abstract]   [Full Text] [Related]  

  • 40. Ethical perspectives in evaluation of telehealth.
    Cornford T; Klecun-Dabrowska E
    Camb Q Healthc Ethics; 2001; 10(2):161-9. PubMed ID: 11302093
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.